

Dr Thomas Hugh Massey

MA MSci BM BCh DPhil MRCP (Neurology)

Address : Cardiff University
Cardiff CF24 4HQ, UK

Email : MasseyT1@cardiff.ac.uk
GMC Number : 7040601

Current positions

2023 - present Senior Clinical Research Fellow in Neurology, Cardiff University
2023 - present Group Leader, UK Dementia Research Institute at Cardiff
2021 - present Consultant Neurologist, Cardiff & Vale University Health Board

Previous positions

2013 - 2021 Clinical Research Fellow and Neurology Registrar, Cardiff University
2009 - 2013 Junior doctor in Neurology and Internal Medicine, Severn Deanery

Education and Qualifications

2021 Certificate of Completion of Training (Neurology). Entry onto Specialist Register
2020 Neurology Specialty Certificate Examination (SCE)
2012 Membership of the Royal College of Physicians (MRCP) UK
2009 BM BCh (Medicine and Surgery) with distinction, Keble College, Oxford University
2004 DPhil (Biochemistry). DNA recombination/repair; supervisor Prof David Sherratt
Magdalen College, Oxford University
2000 MA MSci in Natural Sciences (Biochemistry). First Class.
Gonville and Caius College, Cambridge University

Fellowships, Awards, Prizes

2023 - 2028 MRC Clinician Scientist Fellowship
2022 UK Clinical academic trainee conference poster prize (first place)
2021 - 2023 Guarantors of Brain post-CCT clinical research Fellowship
2016 - 2019 MRC clinical research training Fellowship (post-doctoral)
2016 - 2019 Patrick Berthoud Charitable Trust/ABN research Fellowship (consumables)
2013 - 2021 Welsh Clinical Academic Training (WCAT) Fellowship in Neurology
2005 - 2009 Keble College scholarships and prize in Medicine
2001 - 2004 Microbiology scholarship and Magdalen College Research Prize (2004).

Academic Activities

Positions of responsibility

2024 - present Co-director, Huntington's Disease Centre in Wales
2023 - present Co-chair elect, UK HD Network
2022 - present Specialty Lead for Neurology and Neurodegeneration clinical research in Wales
2019 - present Co-chair of European HD Network genetic modifiers working group
2017 - present Associate member, Scientific Advisory Board, LoQus23 Therapeutics Ltd

Academic peer review

2018 - present Grants: including MRC, Huntington Society of Canada, Fondazione telethon (Italy)
2016 - present Manuscripts: including Nature Neuroscience, Annals of Neurology, Disease Models

Clinical trials

2023 - present Local Principal Investigator for EXPERTS-ALS and HD trials
2017 - present Local organisation and delivery of intrathecal tominersen trials in HD; Co-I on various HD trials

Selected Grant and Fellowship Funding

2023 - present	MRC Clinician Scientist Fellowship (£2.1 M as PI)
2023 - present	Moondance Foundation (£90 k as PI)
2021 - 2023	Guarantors of Brain Clinical Post Doctoral Fellowship (£65 k as PI)
2021 - 2023	Academy of Medical Sciences Starter Grant for Clinical Lecturers (£24 k as PI)
2021 - 2023	Cure Huntington's Disease Initiative (CHDI; £698 k, PI from June 2022).
2020 - 2023	Ataxia UK (£492 k as co-I. PI Prof Henry Houlden, UCL)
2019 - 2021	LoQus23 Therapeutics Ltd (£535 k as co-I. PI Prof Lesley Jones, Cardiff University)
2016 - 2019	MRC clinical research training Fellowship (post-doctoral; £381 k as PI)
2016 - 2019	Patrick Berthoud Charitable Trust/ABN Fellowship (£30 k as PI)
2016 - 2017	European HD Network (EHDN) seed fund (£20 k as PI)

Selected Publications

1. Kim, KH... **Massey TH...** & Lee, JM. (2024) Posttranscriptional regulation of *FAN1* by miR-124-3p at rs3512 underlies onset-delaying genetic modification in Huntington's disease. *Proc Natl Acad Sci USA*; 121(16):e2322924121. doi: 10.1073/pnas.2322924121.
2. **Massey, TH*** & McLauchlan, DJ (2024) Huntington's disease: a clinical primer for acute and general physicians. *Clin Med (Lond)*, 100200. doi: 10.1016/j.clinme.2024.100200.
3. Hong EP... **Massey TH...** & Lee JM. (2024) Modification of Huntington's disease by short tandem repeats. *Brain Commun.*, 6, fcae016. doi: 10.1093/braincomms/fcae016.
4. Wheeler, V, Stone, J, **Massey TH**, & Mouro Pinto, R (2024) The instability of the Huntington's disease CAG repeat mutation. Book chapter in: *Huntington's Disease - Pathogenic Mechanisms and Implications for Therapeutics* (Eds: Yang, Thompson, Heiman). Academic Press (Elsevier).
5. Stöberl, N... **Massey, TH** & Allen ND (2023) Mutant huntingtin confers cell-autonomous phenotypes on Huntington's disease iPSC-derived microglia. *Sci Rep.*, 13, 20477.
6. McAllister, B, Donaldson, J... & **Massey, TH*** (2022) Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. *Nature Neuroscience* 25, 446-457; doi: 10.1038/s41593-022-01033-5.
7. Lobanov, S... **Massey, TH*** & Jones, L (2022) Huntington's disease age at motor onset is modified by the tandem hexamer repeat in TCERG1. *NPJ Genomic Medicine*, 7, 53. doi: 10.1038/s41525-022-00317-w.
8. Lee, JM ... **Massey TH...** & Gusella, JF (2022) Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. *Am. J. Hum. Genet.*, 109, 885-899.
9. **Massey, TH**, McAllister, B, Rosser, AE & Jones, L. (2022) Author Response: Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease. *Neurology*, 98, 515.
10. **Massey, TH** & Robertson, NP (2021) Medication-overuse headache: causes, consequences and management. *J. Neurol.*, 268, 3505-3507. doi: 10.1007/s00415-021-10720-5
11. Hong, EP... **Massey, TH...** & Lee, JM (2021) Association Analysis of Chromosome X to Identify Genetic Modifiers of Huntington's Disease. *J. Huntingtons Dis.*, 10, 367-375.
12. McAllister, B... & **Massey, TH*** (2021) The timing and impact of psychiatric, cognitive and motor abnormalities in Huntington's disease. *Neurology* doi: 10.1212/WNL.0000000000011893
13. Ellis N... **Massey TH...** Holmans P (2020) Genetic Risk Underlying Psychiatric and Cognitive Symptoms in Huntington's disease. *Biol Psychiatry*, 87, 857-865.
14. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019)* CAG repeat not polyglutamine length determines timing of Huntington's disease onset. *Cell*, 178, 887-900.
15. Tabrizi SJ, Phase 1–2a IONIS-HTTRx Study Site Teams* et al. (2019) Targeting Huntingtin Expression in Patients with Huntington's Disease. *N. Engl. J. Med.*, 380, 2307-2316.
16. Cronin T, Rosser A & **Massey TH*** (2019) Clinical presentation and features of Juvenile-onset Huntington's disease: a systematic review. *J. Huntingtons Dis.*, 8, 171-179.
17. **Massey, TH** & Jones L. (2018) The central role of DNA damage and repair in CAG repeat diseases. *Dis. Model. Mech.*, 11(1), pii: dmm031930. doi: 10.1242/dmm.031930.
18. **Massey, TH...** & Löwe, J. (2006) DNA translocation by hexameric FtsK. *Mol. Cell*, 23, 457-469.
19. **Massey, TH...** & Sherratt, D.J. (2004) Asymmetric activation of Xer recombination by FtsK. *EMBO Rep.*, 5, 309-404.